Mirimus has fused together unparalleled expertise of the RNA interference pathway and genetic engineering of mouse models to create technology platforms for rapid and cost-effective production of customized RNAi-GEMMs with potent, reversible gene silencing. Using the most advanced platform of RNAi technology and mouse production, we can rapidly and efficiently engineer mouse models capable of reversible, fluorescence-coupled gene silencing in vivo. For studies requiring mouse models carrying complex genetics, advanced genome editing technologies can be used to build a high volume of custom-designed models with multiple genetic manipulations in a fraction of the time previously required. Our innovative pipeline eliminates the long lead-time for multiple ES cell targeting modifications, mouse generation, intercrossing, colony expansion and functional validation, as well as prediction of toxicological effects caused by global gene suppression.

Mirimus uses the TET-system to enable inducible and reversible RNAi mediated gene silencing and precise genome engineering in ESCs. See here for more details (link to ESC targeting). Targeted ESC clones are rigorously screened prior to mouse generation. Targeted ESCs can be used to directly generate founder mice via microinjection.

Using this approach chimeric founder mice can be generated in approximately six months. If validated shRNAs are available in our inventory, founder mice can be generated in as little as three months.
fig8
Mirimus operates using a fully validated pipeline for rapid validation of knockdown in RNAi ES cells. The system is modular and can be adapted for either systemic or tissue-specific gene knockdown, as well as overexpression of cDNAs. All ES cell lines are cryopreserved until mouse production is requested by investigators. Mouse lines can be derived and are ready for experimental use in as little as 6-8 weeks.
Our RNAi GEMMs enable the unprecedented ability for rapid identification and validation of drug targets, as well as prediction of toxicological effects caused by global gene suppression.
fig9

Charles Rivers Laboratory blastocyst injection services for mouse cohort generation (3-8 mice)
(CRL Service)
20 wks